Lumiracoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to manage pain and inflammation associated with conditions such as osteoarthritis and rheumatoid arthritis. It selectively inhibits the COX-2 enzyme involved in the inflammatory process, reducing pain, swelling, and stiffness while having minimal impact on the COX-1 enzyme, which protects the stomach lining and thereby lowers the risk of gastrointestinal side effects compared to non-selective NSAIDs. It is also effective for acute pain relief, such as back pain or muscle pain, and improves joint function and mobility in patients with chronic joint conditions. Administered orally, it is a preferred option for long-term pain management in at-risk patients. However, its use requires careful medical supervision due to potential risks of liver toxicity and cardiovascular events, and it is not recommended for individuals with pre-existing liver conditions.